Epidemiologic studies of adverse effects of anti-retroviral drugs: How well is statistical power reported

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 3, 2005, Pages 155-161

  Halpern, Scott D ^a   Barton, Todd D ^a   Gross, Robert ^a   Hennessy, Sean ^a   Berlin, Jesse A ^a   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse drug effects; Anti retroviral drugs; Research ethics; Research reporting; Statistical power

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG SURVEILLANCE PROGRAM; EMBASE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION RETRIEVAL; MANDATORY REPORTING; MEDLINE; NON PROFIT ORGANIZATION; OUTCOMES RESEARCH; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESEARCH ETHICS; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; HUMANS; ORGANIZATIONAL AFFILIATION; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; RESEARCH SUPPORT; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 14944354069     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1059     Document Type: Article

References (33)

1. Venning GR. Identification of adverse reactions to new drugs. II - how were 18 important adverse reactions discovered and with what delays? Br Med J 1983; 286: 289-292.
2. Temple RJ, Jones JK, Crout JR. Adverse effects of newly marketed drugs. N Engl J Med 1979; 300: 1046-1047.
3. Strom BL. What is pharmacoepidemiology? In Pharmacoepidemiology (3rd edn), Strom BL (ed.). John Wiley & Sons: New York, 2000; 3-15.
4. Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288: 358-362.
5. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-443.
6. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials. JAMA 2003; 290: 921-928.
7. Kjaergard LL, Gluud C. Funding, disease area, and internal validity of hepatobiliary randomized clinical trials. Am J Gastroenterol 2002; 97: 2708-2713.
8. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. Br Med J 2002; 325: 249-252.
9. Halpern SD, Karlawish JHT. Industry-sponsored research [letter]. Lancet 2000; 356: 2193.
10. Djulbegovic B, Bennett CL, Lyman GH. Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoieten. Blood 1999; 94: 399a.
11. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000; 356: 635-638.
12. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986; 1: 155-158.
13. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-872.
14. Dickersin K, Min Y-I, Meinert CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992; 267: 374-378.
15. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
16. Ioannidis JPA. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-286.
17. Ioannidis JPA. Time lag bias in publishing clinical trials. JAMA 1998; 279: 1952-1953.
18. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. Br Med J 1997; 315: 640-645.
19. Braitman LE. Confidence intervals assess both clinical significance and statistical significance. Ann Intern Med 1991; 114: 515-517.
20. Young MJ, Bresnitz EA, Strom BL. Sample size nomograms for interpreting negative clinical studies. Ann Intern Med 1983; 99 248-251.
21. Makuch RW, Johnson MF. Some issues in the design and interpretation of 'negative' clinical trials. Arch Intern Med 1986; 146: 986-989.
22. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282: 1453-1457.
23. Spurgeon D. Trials sponsored by drug companies: review ordered. Br Med J 1998; 317: 618.
24. Baird P, Downie J, Thompson J. Clinical trials and industry. Science 2002; 287: 2211.
25. DeAngelis CD, Fontanarosa PB, Flanagin A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA 2001; 286: 89-91.
26. Drazen JM, Curfman GD. Financial associations of authors. N Engl J Med 2002; 346: 1901-1902.
27. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, accountability. Ann Intern Med 2001; 135: 463.
28. James A, Horton R. The Lancet's policy on conflicts of interest. Lancet 2003; 361: 8-9.
29. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-1991.
30. Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for reporting of Diagnostic Accuracy Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003; 138: 40-44.
31. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials. Lancet 1999; 354: 1896-1900.
32. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-2012.
33. Moher D, Jones A, Lepage L, CONSORT Group. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001; 285: 1992-1995.